Implantable Sensor Market projected to reach US$ 11,415.62 million by 2027 | DexCom, Pinnacle Technology, GluSense, Sensirion AG

Implantable sensors have been used in medical research for measuring parameters, such as force, torque, pressure, and temperature inside the human body. These advanced sensor systems must be small in size, compatible with human tissue, and sturdy enough to withstand the human body's physical forces. They must also be self-powered and able to transmit data wirelessly. Ideal sensor systems are robust and straightforward, which minimizes the possibility of malfunction or failure. Innovations in the development of point-of-care medical sensors, technological advancements for monitoring & diagnosis of the patient, and improvement in technical design—which would enhance the functions of implantable sensors for the quality of life and longevity—are expected to propel the growth of the market. Increasing incidence of cancer, heart failure, and other diseases has stimulated research on developing novel implantable devices for the localized treatment of cancer. Cancer is currently the second-largest cause of death worldwide, after cardiovascular disease. Current trends also suggest that cancer would become the leading cause of death by 2030. Implantable sensors should be integrated with other technologies to overcome all these challenges.

Request For Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPRE00016982/?openpr-10144

Competitive Landscape Microcatheters Market:

Analog Devices, Inc.
DexCom, Inc.
GluSense Ltd.
HONEYWELL INTERNATIONAL INC.
Medtronic
NXP Semiconductors N.V.
Pinnacle Technology, Inc.
Sensirion AG
TE Connectivity
Texas Instruments Incorporated

The implantable sensor market was valued at US$ 4,912.00 million in 2019 and it is projected to reach US$ 11,415.62 million by 2027; it is expected to grow at a CAGR of 11.1% during 2020–2027.

Based on type, the implantable sensor market is segmented into glucose sensor, temperature sensor, oxygen sensor, pressure sensor, and others. The glucose sensor segment held the largest share of the market in 2019, whereas the oxygen sensor segment is anticipated to register the highest CAGR in the market during the forecast period. Many companies are developing implantable sensor for diabetes. For instance, Integrated Medical Sensors is developing an implantable CGM the size of a sesame seed. Further, Profusa is developing implantable sensors based on its proprietary Lumee Oxygen platform that could continually monitor glucose readings and other biomarkers.

Mobile healthcare technologies offer a great potential for improving patient care and reducing healthcare costs. Implantable and wearable technologies subsidize to a transformation in the mobile health era in terms of improving healthcare and health outcomes and providing real-time management on enhanced health management and tracking. Further, mobile technologies are paving the way for revolutionizing the diagnosis of diseases and monitoring patient treatment. Mobile sensors are helping in everything from monitoring our movements and sleeps to record the electrical activity in our hearts 24/7 as we go about our daily routines. As a result, the technology is quickly becoming vital for researching ways to cure illness and improve health.

Most cardiac rhythm management companies have applications that physicians and device technicians can access to track their patients with pacemakers and implantable cardioverter defibrillators, enrolled in remote patient management programs. All current-generation cardiac rhythm management devices are capable of remote transmission. Newer pacemakers and implantable cardioverter-defibrillators have Bluetooth LE transmission capability to create a straightforward way to share device data to patient-centered applications. As all cardiac rhythm management companies have built secure data platforms to receive remotely transmitted implanted device data, there is an opportunity to expand these platforms and include patient-facing software applications. The new generation of implantable hemodynamic sensors for heart failure management provides web- and app-based data to physicians to allow for physician-directed patient self-management of remotely transmitted intracardiac pressures.

Various companies operating in the implantable sensor market use strategies, such as product launches, mergers and acquisitions, collaborations, product innovations, and product portfolio expansions, to expand their footprint worldwide, maintain the brand name, and meet the growing demand from end users.

Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00016982/?openpr-10144

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.